Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Set to enter hospice care, a patient with idiopathic multicentric Castleman's disease is now in remission after treatment with a medication identified by an AI-guided analysis.

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic macular edema with ...

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The Cannabis Regulatory Agency found medium chain triglyceride (MCT) oil, a prohibited ingredient, in Platinum brand vaping ...

State leaders are reviving talk of importing prescription drugs from Canada, even as US drugmakers and health-care attorneys ...

"Yo-yo" dieting --- repeatedly losing and gaining weight -- can significantly increase risk of kidney disease among people ...